Syros Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
07 September 2023 - 10:30PM
Business Wire
Syros Pharmaceuticals (NASDAQ:SYRS), a biopharmaceutical company
committed to advancing new standards of care for the frontline
treatment of hematologic malignancies, today announced the grant of
restricted stock unit (RSU) awards for an aggregate of 20,650
shares of Syros common stock to two newly hired employees in
connection with commencing employment with Syros. These RSUs were
granted as a material inducement to employment in accordance with
Nasdaq Listing Rule 5635(c)(4).
The awards were granted on September 1, 2023, and vest as to
one-quarter of the shares on August 31, 2024, and as to an
additional one-quarter of the shares at the end of each successive
year thereafter, subject to the employee’s continued service with
Syros. These awards are subject to the terms and conditions of a
restricted stock unit agreement covering the awards and Syros’ 2022
Inducement Stock Incentive Plan.
About Syros Pharmaceuticals
Syros is committed to developing new standards of care for the
frontline treatment of patients with hematologic malignancies.
Driven by the motivation to help patients with blood disorders that
have largely eluded other targeted approaches, Syros is advancing a
robust late-stage clinical pipeline, including tamibarotene, an
oral selective RARα agonist in patients with higher-risk
myelodysplastic syndrome and acute myeloid leukemia with RARA gene
overexpression, and SY-2101, a novel oral form of arsenic trioxide
in patients with acute promyelocytic leukemia. Syros is also
seeking out-licensing opportunities for SY-5609, a highly selective
and potent clinical-stage CDK7 inhibitor for the treatment of
select solid tumors, and multiple preclinical programs in oncology.
For more information, visit www.syros.com and follow us on Twitter
(@SyrosPharma) and LinkedIn.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20230907173442/en/
Syros Contact Karen Hunady Director of Corporate
Communications & Investor Relations 1-857-327-7321
khunady@syros.com Investor Contact Hannah Deresiewicz Stern
Investor Relations, Inc. 212-362-1200
hannah.deresiewicz@sternir.com
Syros Pharmaceuticals (NASDAQ:SYRS)
Historical Stock Chart
Von Apr 2024 bis Mai 2024
Syros Pharmaceuticals (NASDAQ:SYRS)
Historical Stock Chart
Von Mai 2023 bis Mai 2024